• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Masimo Corporation

    7/17/24 5:29:36 PM ET
    $MASI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $MASI alert in real time by email
    SC 13D/A 1 tm2419696d1_sc13da.htm SC 13D/A

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13D

    (Rule 13d-101)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(a)

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 13)*

     

    Masimo Corporation

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    574795100

    (CUSIP Number)

     

    Quentin Koffey

    Politan Capital Management LP

    106 West 56th Street, 10th Floor

    New York, New York 10019

    646-690-2830

     

    With a copy to:

     

    Richard M. Brand

    Cadwalader, Wickersham & Taft LLP

    200 Liberty Street

    New York, NY 10281

    212-504-6000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    July 17, 2024

    (Date of Event Which Requires Filing of This Statement)

     

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ¨

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 574795100   Page 2

     

    1

    NAME OF REPORTING PERSON

    Politan Capital Management LP

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) x  (b) ¨

    3 SEC USE ONLY
    4

    SOURCE OF FUNDS

     

    OO (See Item 3)

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    Number of
    shares
    beneficially
    owned by
    each
    reporting
    person
    with
    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    4,713,518

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    4,713,518

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,713,518

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    8.9%*

    14

    TYPE OF REPORTING PERSON

     

    IA

    * All percentage calculations set forth herein are based upon the aggregate of 53,182,247 shares of Common Stock outstanding as of June 13, 2024, as reported in the Issuer’s definitive proxy statement, filed with the Securities and Exchange Commission (the “SEC”) on June 17, 2024 (the “Issuer Proxy Statement”). 

     

     

    CUSIP No. 574795100   Page 3

     

    1

    NAME OF REPORTING PERSON

    Politan Capital Management GP LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) x  (b) ¨

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    OO (See Item 3)

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    Number of
    shares
    beneficially
    owned by
    each
    reporting
    person
    with
    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    4,713,518

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    4,713,518

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,713,518

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    8.9%*

    14

    TYPE OF REPORTING PERSON

     

    IA

    * All percentage calculations set forth herein are based upon the aggregate of 53,182,247 shares of Common Stock outstanding as of June 13, 2024, as reported in the Issuer Proxy Statement. 

     

     

    CUSIP No. 574795100   Page 4

     

    1

    NAME OF REPORTING PERSON

    Politan Capital Partners GP LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) x  (b) ¨

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    OO (See Item 3)

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    Number of
    shares
    beneficially
    owned by
    each
    reporting
    person
    with
    7

    SOLE VOTING POWER

     

    0

    8

    SHARED VOTING POWER

     

    4,713,518

    9

    SOLE DISPOSITIVE POWER

     

    0

    10

    SHARED DISPOSITIVE POWER

     

    4,713,518

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,713,518

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    8.9%*

    14

    TYPE OF REPORTING PERSON

     

    IA

    * All percentage calculations set forth herein are based upon the aggregate of 53,182,247 shares of Common Stock outstanding as of June 13, 2024, as reported in the Issuer Proxy Statement.  

     

     

    CUSIP No. 574795100   Page 5

     

    1

    NAME OF REPORTING PERSON

    Quentin Koffey

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) x  (b) ¨

    3

    SEC USE ONLY

     

    4

    SOURCE OF FUNDS

     

    OO (See Item 3)

    5

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

    ¨

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    Number of
    shares
    beneficially
    owned by
    each
    reporting
    person
    with
    7

    SOLE VOTING POWER

     

    1,228

    8

    SHARED VOTING POWER

     

    4,713,518

    9

    SOLE DISPOSITIVE POWER

     

    1,228

    10

    SHARED DISPOSITIVE POWER

     

    4,713,518

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,714,746*

    12

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    8.9%**

    14

    TYPE OF REPORTING PERSON

     

    IN

    * Includes Mr. Koffey’s 1,228 restricted share units granted to him on June 26, 2023 by virtue of his position as a director on the Board and that vested on June 26, 2024.

    ** Mr. Koffey’s percentage calculations set forth herein are based upon the aggregate of 53,182,247 shares of Common Stock outstanding as of June 13, 2024, as reported in the Issuer Proxy Statement.  

     

     

    CUSIP No. 574795100   Page 6

     

    This Amendment No. 13 to Schedule 13D (this “Amendment No. 13”) amends and supplements the Schedule 13D filed on August 16, 2022 (as amended and supplemented through the date of this Amendment No. 13, collectively, the “Schedule 13D”) by the Reporting Persons, relating to the common stock, par value $0.001 per share, of Masimo Corporation, a Delaware corporation (the “Issuer”). Capitalized terms not defined in this Amendment No. 13 shall have the meaning ascribed to them in the Schedule 13D.

     

    The information set forth in response to Item 4 below shall be deemed to be a response to all Items where such information is relevant.

     

    ITEM 4. PURPOSE OF TRANSACTION

     

    Item 4 of the Schedule 13D is hereby amended and supplemented with the following information:

     

    On July 17, 2024, Politan, a Reporting Person, filed a lawsuit (the “Complaint”) in the Delaware Court of Chancery (the “Court”) against the Issuer and three of its directors (the “Defendants”) seeking to cause the 2024 Annual Meeting of the Issuer to be held as soon as possible, in addition to other relief, including ensuring that the 2024 Annual Meeting cannot be delayed any further.

     

    Both Delaware law and the Issuer’s own Bylaws require the Issuer to hold each annual stockholder meeting within 13 months of the previous years’ meeting. On July 16, 2024, the Issuer announced the postponement of the 2024 Annual Meeting from July 25, 2024 (a date that was itself 13 months after the 2023 annual meeting) to September 19, 2024. This postponement followed closely on the announcements by both of the leading proxy advisors, Institutional Shareholder Services  and Glass, Lewis & Co., recommending that the Issuer’s stockholders vote for Politan’s nominees at the 2024 Annual Meeting. The Complaint alleges that the two month delay was unnecessary, as Politan had previously notified the Issuer that concerns with respect to apparent empty voting could be resolved by setting a record date as soon as July 18, 2024 and holding the 2024 Annual Meeting in the first week of August.

     

    The Complaint seeks to protect the stockholder franchise and prevent the manipulation of the corporate machinery to unnecessarily delay the 2024 Annual Meeting and entrench the incumbent directors in office.

     

    The Complaint seeks the following relief: (i) a determination that the director Defendants breached their fiduciary duties by postponing the 2024 Annual Meeting; (ii) an order that the Issuer must set the record date for the 2024 Annual Meeting for as soon as possible; (iii) an order that as a matter of Delaware law the Issuer must hold the 2024 Annual Meeting as soon as possible; (iv) a declaration that the Defendants are estopped from rejecting the nominations of Politan’s nominees to the 2024 Annual Meeting; and (v) an appropriate status quo order to prevent the Defendants from taking any material action with respect to the business of the Issuer before the 2024 Annual Meeting. 

     

    ITEM 7. MATERIAL TO BE FILED AS AN EXHIBIT

     

    Exhibit 99.1 Joint Filing Agreement among Politan Capital Management LP, Politan Capital Management GP LLC, Politan Capital Partners GP LLC, and Quentin Koffey*
       
    Exhibit 99.2 Trading Data*
       
    Exhibit 99.3 Trading Data*
       
    Exhibit 99.4 Form of Verified Complaint, filed with the Delaware Court of Chancery on October 21, 2022*
       
    Exhibit 99.5 Form of Second Amended and Supplemented Complaint, filed as an Exhibit to the Motion for Leave to Amend with the Delaware Court of Chancery on March 10, 2023*
    Exhibit 99.6 Form of Engagement and Indemnification Agreement entered into by and between Politan Capital Management LP and Michelle Brennan*
    Exhibit 99.7 Trading Data*
    Exhibit 99.8 Press Release, dated June 26, 2023*
    Exhibit 99.9 Form of Engagement and Indemnification Agreement entered into by and between Politan Capital Management LP and each of William Jellison and Darlene Solomon*
    Exhibit 99.10 Demand Letter, dated May 8, 2024*
    Exhibit 99.11 Politan Letter, dated May 9, 2024*
    Exhibit 99.12 Politan Letter, dated July 3, 2024*
    Exhibit 99.13 Politan Letter, dated July 12, 2024*
    Exhibit 99.14 Politan Letter, dated July 15, 2024*

     

    *Previously filed.

     

     

    CUSIP No. 574795100   Page 7

     

    SIGNATURES

     

    After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: July 17, 2024

     

      POLITAN CAPITAL MANAGEMENT LP
       
      By: Politan Capital Management GP LLC,
        its general partner
         
      By: /s/ Quentin Koffey
        Name: Quentin Koffey
        Title: Managing Member
           
      POLITAN CAPITAL MANAGEMENT GP LLC
       
      By: /s/ Quentin Koffey
        Name: Quentin Koffey
        Title: Managing Member
           
      POLITAN CAPITAL PARTNERS GP LLC
       
      By: /s/ Quentin Koffey
        Name: Quentin Koffey
        Title: Managing Member
           
      QUENTIN KOFFEY
         
      By: /s/ Quentin Koffey
        Name: Quentin Koffey

     

     

     

    CUSIP No. 574795100   Page 8

     

    INDEX TO EXHIBITS

     

    Exhibit

    Description

    Exhibit 99.1 Joint Filing Agreement among Politan Capital Management LP, Politan Capital Management GP LLC, Politan Capital Partners GP LLC, and Quentin Koffey*
       
    Exhibit 99.2 Trading Data*
       
    Exhibit 99.3 Trading Data*
       
    Exhibit 99.4 Form of Verified Complaint, filed with the Delaware Court of Chancery on October 21, 2022*
       
    Exhibit 99.5

    Form of Second Amended and Supplemented Complaint, filed as an Exhibit to the Motion for Leave to Amend with the Delaware Court of Chancery on March 10, 2023*

     

    Exhibit 99.6 Form of Engagement and Indemnification Agreement entered into by and between Politan Capital Management LP and Michelle Brennan*
    Exhibit 99.7 Trading Data*
    Exhibit 99.8 Press Release, dated June 26, 2023*
    Exhibit 99.9 Form of Engagement and Indemnification Agreement entered into by and between Politan Capital Management LP and each of William Jellison and Darlene Solomon*
    Exhibit 99.10 Demand Letter, dated May 8, 2024*
    Exhibit 99.11 Politan Letter, dated May 9, 2024*
    Exhibit 99.12 Politan Letter, dated July 3, 2024*
    Exhibit 99.13 Politan Letter, dated July 12, 2024*
    Exhibit 99.14 Politan Letter, dated July 15, 2024*

     

    *Previously filed.

     

     

     

    Get the next $MASI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MASI

    DatePrice TargetRatingAnalyst
    12/27/2024$170.00 → $194.00Outperform
    Raymond James
    11/6/2024$170.00Mkt Perform → Outperform
    Raymond James
    6/3/2024$126.00 → $160.00Neutral → Overweight
    Piper Sandler
    4/15/2024$148.00 → $170.00Hold → Buy
    Stifel
    3/25/2024$117.00 → $160.00Equal Weight → Overweight
    Wells Fargo
    1/30/2024$107.00 → $121.00Buy → Hold
    Jefferies
    1/3/2024Buy → Hold
    Needham
    11/8/2023Outperform → Mkt Perform
    Raymond James
    More analyst ratings

    $MASI
    Leadership Updates

    Live Leadership Updates

    See more
    • Dexcom Appoints Jon Coleman as Chief Commercial Officer

      DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global commercial organization, including global sales, marketing and customer experience. Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (NASDAQ:MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo's commercial teams where he oversaw the consolid

      3/25/25 4:05:00 PM ET
      $DXCM
      $MASI
      $PFE
      Medical/Dental Instruments
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Biotechnology: Pharmaceutical Preparations
    • Masimo Announces Leadership Transition

      Katie Szyman Appointed Chief Executive Officer and to Board of Directors Interim CEO Michelle Brennan Named Chairman of Masimo's Board Today the Board of Directors (the "Board") of Masimo (NASDAQ:MASI), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief Executive Officer ("CEO") of the Company. Interim CEO Michelle Brennan has been appointed Chairman of Masimo's Board and Lead Independent Director Quentin Koffey has been appointed Vice Chairman. All of these changes are effective as of February 12, 2025. Ms. Szyman is currently worldwide president of Advanced Patient Monitoring at BD (Becton, Dickinson and Company). Previously, Ms. Szyman

      1/21/25 4:00:00 PM ET
      $MASI
      $NARI
      $OM
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medical/Dental Instruments
    • Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors

      Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns

      10/18/24 9:00:00 AM ET
      $ENV
      $LH
      $MASI
      $MSCI
      Business Services
      Consumer Discretionary
      Medical Specialities
      Health Care